[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363680-105":59,"doc-detail-363680-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","purinergic-activity-of-circulating-extracellular-vesicles-associates-with-disease-progression-in-melanoma","Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma","","Extracellular vesicles (EVs) produced by melanoma cells carry ecto-nucleotidases CD39/CD73 that generate adenosine (ADO) and deliver it to immune cells, promoting immune suppression. Using plasma from melanoma patients with no evidence of disease (NED) or metastatic disease, EVs were analyzed by separating melanoma cell-derived vesicles (MTEX) from non-malignant cell-derived vesicles (NTEX). High-pressure liquid chromatography with fluorescence detection quantified purinergic activity. NTEX showed higher purinergic activity than MTEX, while only CD73 activity in total EVs correlated with disease progression, increasing significantly in metastatic patients. Results support total EV purinergic activity as a clinically meaningful estimate of ADO-driven immune suppression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/purinergic-activity-of-circulating-extracellular-vesicles-associates-with-disease-progression-in-melanoma/363680/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/purinergic-activity-of-circulating-extracellular-vesicles-associates-with-disease-progression-in-melanoma/363680.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do melanoma-derived extracellular vesicles (EVs) play in immune suppression?","Question",{"text":112,"@type":113},"Melanoma-derived EVs carry CD39/CD73 on their surface, producing adenosine (ADO) and delivering it to immune recipient cells, which induces immune suppression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were EVs obtained and analyzed to compare MTEX and NTEX?",{"text":117,"@type":113},"EVs were isolated from plasma of melanoma patients, MTEX were separated from non-malignant EVs (NTEX) using immune capture with anti-CSPG4 monoclonal antibodies, and purinergic activity was measured using HPLC with fluorescence detection.",{"name":119,"@type":110,"acceptedAnswer":120},"Which EV-related purinergic measurement correlated with melanoma disease progression?",{"text":121,"@type":113},"CD73 activity in total EVs correlated with disease progression, being significantly higher in patients with metastatic disease than those with no evidence of disease (P = 0.02).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363680,1790193858,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE     \nPurinergic activity of circulating extracellular vesicles associates with disease progression in melanoma  \nYana G. Najjara , Chang Sook Honga, b, Elizabeth V. Menshikovac, John M. Kirkwooda , Brenda Diergaardea,d , Edwin K. Jacksonc  and Theresa L. Whitesidea, b   \naUPMC Hillman Cancer Center, Pittsburgh, PA, USA; bDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; cDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; dDepartment of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA  \nABSTRACT  \nExtracellular vesicles (EVs) produced by melanoma cells (MTEX) carry ecto-nucleotidases, CD39/CD73, on their surface membrane, produce adenosine (ADO), and deliver it to immune recipient cells, inducing immune suppression. Based on studies of MTEX from melanoma cell lines, we hypothesized that MTEX are the major producers of ADO in cancer patients’ plasma, which contains a variable mix of MTEX and NTEX. To test this hypothesis, EVs were isolated from the plasma of melanoma patients with no evidence of disease (NED) or with metastatic disease at phlebotomy, and MTEX were separated from EVs produced by non-malignant cells (NTEX) by immune capture using anti-CSPG4 mAbs. The purinergic activity of CD39/CD73 in total plasma EVs and NTEX was measured by high-pressure liquid chromatography with fluorescence detection, and that in MTEX was calculated. Unexpectedly, NTEX showed higher levels of purinergic activity than MTEX. While higher purinergic activity of NTEX vs. MTEX was not associated with disease status, the CD73 activity in total EVs was correlated with disease progression: it was significantly higher in patients with metastatic disease compared to those with NED (P = 0.02). Our data suggest that in the plasma of cancer patients, both MTEX and NTEX contribute to the purinergic metabolism mediated by EVs. Thus, the total EV fraction in plasma of melanoma patients provides a clinically meaningful assessment of purinergic activity and potentially can serve as a personalized estimate of levels of ADO-driven immune suppression in patients.  \nARTICLE HISTORY  \nReceived 7 October 2025 Revised 24 April 2026 Accepted 2 June 2026  \nKEYWORDS  \nExtracellular vesicles (EVs); melanoma cell-derived vesicles (MTEX); purinergic activity; CD39/CD73 signaling; MTEX-driven molecular reprogramming  \nIntroduction  \nTherapy with immune checkpoint inhibitors (ICIs) has achieved remarkable results in many different types of cancer 1,2 but has failed to provide durable benefits in a significant proportion of patients.3 While reasons for primary or acquired resistance to ICIs are complex and still being elucidated, tumor-induced immune suppression may be one of the mechanisms of resistance to ICIs.3,4 Cancers produce numerous factors that limit the efficacy of ICI4-6 by altering the tumor microenvironment (TME) into an immune“desert”, either devoid of immune effector cells or populated by exhausted and ineffective immune cells.7 The adenosinergic pathway is emerging as a major mechanism of resistance to immune-based therapies in various cancers.8 Adenosine (ADO) and its biological effects, including immune suppression in cancer, have been intensively investigated for many years.9 Earlier studies identified the actionable components of the adenosinergic pathway, i.e., adenosine receptors (ADOR), ligands and enzymes mediating ADO synthesis and degradation. 10 ADO, which is abundantly produced by most tumors, has long been known to mediate tumor-induced immune suppression through ADOR subtypes (particularly A2AR and A2BR) that trigger signaling which directly impairs the activity of cytolytic T cells 11 and promotes activity of regulatory T cells and/or immunosuppressive macrophages.12 ADO has become a therapeutic target in cancer, and various strategies to block or impair its suppressive activity are curr","cbCaihGDFlTlM8kL","https://ap.wps.com/l/cbCaihGDFlTlM8kL","pdf",1609115,14,"English","# Abstract\n# Introduction\n## Immune checkpoint therapy resistance\n## Adenosinergic pathway and immune suppression\n## Rationale for EV-mediated ADO signaling","[{\"question\":\"What role do melanoma-derived extracellular vesicles (EVs) play in immune suppression?\",\"answer\":\"Melanoma-derived EVs carry CD39/CD73 on their surface, producing adenosine (ADO) and delivering it to immune recipient cells, which induces immune suppression.\"},{\"question\":\"How were EVs obtained and analyzed to compare MTEX and NTEX?\",\"answer\":\"EVs were isolated from plasma of melanoma patients, MTEX were separated from non-malignant EVs (NTEX) using immune capture with anti-CSPG4 monoclonal antibodies, and purinergic activity was measured using HPLC with fluorescence detection.\"},{\"question\":\"Which EV-related purinergic measurement correlated with melanoma disease progression?\",\"answer\":\"CD73 activity in total EVs correlated with disease progression, being significantly higher in patients with metastatic disease than those with no evidence of disease (P = 0.02).\"}]","Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma | PDF",1790152624,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6af08e7b0592c9982b8dbbe8530481ef.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/835cebfb56b515ac10a2fe00c4759cfc.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dbeb679be43f28eb24ee9cd6644180e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f682b06ec9f9ac26a83798b5908635d.webp",980,1306]